

**Remarks**

Claims 105-123 are pending. Applicants amended claims 105-108. The Specification provides support for the amendment of claim 105, e.g. all the compounds in table 5. Claims 106-108 have been amended to comply with formatting formalities. No new matter has been introduced by the instant amendment.

**Claim objections**

Claims 110-123 stand objected to as being drawn to an invention non-elected by the applicant following a restriction requirement.

Applicants elected group (I) without traverse while requesting rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention. Applicants believe that claims 110-123 are eligible for rejoinder as they depend from or otherwise require all the limitation of the allowable claim 105. Applicants have properly indicated that the non-elected subject matter is withdrawn.

Applicants respectfully request withdrawal of the restriction requirement upon allowance of claim 105 and request examination of the non-elected method claims 110-123 on the merits in compliance with the provisions of 37 CFR 1.144.


**Claim Rejection, 35 U.S.C. § 112, 2<sup>nd</sup> Paragraph**

Claims 105-109 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as invention. Applicants respectfully traverse.


Applicants amended claim 105 to address Examiner's concern.

Claim 107 stands rejected 35 U.S.C. § 112, second paragraph, as allegedly having insufficient antecedent for the following limitations: "6-hydroxyphenyl" in the 10<sup>th</sup> specie and 4-methylpiperazin-1-yl" in the 6<sup>th</sup> specie. Applicants respectfully disagree with the Examiner's assertion. The following compounds

N-Cyclopropyl-4-methyl-3-{4-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-benzamide:



and N-Cyclopropyl-3-(6-hydroxy-4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-4-methyl-benzamide:



have clear antecedent. These compounds are disclosed on pages 55 and 56 respectively.


Therefore, Applicants respectfully request withdrawal of the 35 U.S.C. § 112, second paragraph rejection.

### Conclusion

Applicants have addressed each and every issue set forth by the Examiner. Applicants respectfully submit that claims 105-109 are in good condition for allowance and that claims 110-123 are eligible for rejoinder. Applicants respectfully request examination of the method claims 110-123 on the merits.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-4125.

Respectfully submitted,

  
 Mark W. Milstead  
 Attorney for Applicant  
 Reg. No. 45,825

Novartis Institutes for Biomedical Research  
 NIBR Patents  
 220 Massachusetts Ave.  
 Cambridge, MA 02139  
 (617) 871-4125

Date: *MARCH 6, 2009*